X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (653) 653
Book Review (93) 93
Publication (85) 85
Newsletter (14) 14
Book Chapter (6) 6
Conference Proceeding (2) 2
Newspaper Article (2) 2
Trade Publication Article (2) 2
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
enfuvirtide (574) 574
index medicus (480) 480
humans (418) 418
hiv (268) 268
hiv infections - drug therapy (244) 244
hiv-1 - drug effects (190) 190
infectious diseases (187) 187
virology (181) 181
fusion inhibitor (140) 140
pharmacology & pharmacy (136) 136
immunodeficiency-virus type-1 (133) 133
hiv fusion inhibitors - pharmacology (131) 131
hiv infections - virology (131) 131
hiv-1 (131) 131
male (125) 125
peptide fragments - pharmacology (122) 122
antiviral agents (121) 121
female (120) 120
hiv envelope protein gp41 - pharmacology (118) 118
gp41 (116) 116
peptide fragments - therapeutic use (114) 114
immunology (113) 113
hiv envelope protein gp41 - therapeutic use (112) 112
peptides (105) 105
infection (103) 103
adult (102) 102
amino acid sequence (95) 95
hiv-1 - genetics (95) 95
molecular sequence data (93) 93
hiv fusion inhibitors - therapeutic use (91) 91
antiretroviral therapy (90) 90
human immunodeficiency virus--hiv (89) 89
drug therapy (87) 87
t-20 (87) 87
aids/hiv (86) 86
human-immunodeficiency-virus (86) 86
middle aged (84) 84
hiv envelope protein gp41 - genetics (81) 81
hiv infection (80) 80
anti-hiv agents - pharmacology (78) 78
anti-hiv agents - therapeutic use (78) 78
drug resistance, viral (75) 75
aids (74) 74
envelope glycoprotein (74) 74
hiv envelope protein gp41 - chemistry (73) 73
microbiology (73) 73
hiv-1 - physiology (71) 71
research (71) 71
resistance (71) 71
viruses (69) 69
peptide (68) 68
entry inhibitors (65) 65
entry (64) 64
mutation (64) 64
animals (62) 62
drug resistance (62) 62
antiretroviral drugs (60) 60
hiv envelope protein gp41 - metabolism (59) 59
viral load (58) 58
pharmacokinetics (57) 57
biochemistry & molecular biology (56) 56
health aspects (56) 56
peptide fragments - administration & dosage (56) 56
hiv envelope protein gp41 - administration & dosage (55) 55
therapy (55) 55
efficacy (53) 53
peptides - pharmacology (53) 53
cd4 lymphocyte count (52) 52
hiv fusion inhibitors - administration & dosage (52) 52
hiv fusion inhibitors - chemistry (51) 51
human immunodeficiency virus (51) 51
treatment outcome (50) 50
drug resistance, viral - genetics (49) 49
peptide fragments - adverse effects (49) 49
analysis (48) 48
hiv envelope protein gp41 - adverse effects (48) 48
antiviral activity (46) 46
safety (45) 45
fusion (44) 44
peptides - chemistry (44) 44
virus internalization - drug effects (44) 44
proteins (43) 43
cell line (42) 42
hiv-1-infected patients (41) 41
peptide inhibitor (41) 41
raltegravir (41) 41
drug therapy, combination (40) 40
fusion inhibitors (40) 40
ritonavir (40) 40
dosage and administration (39) 39
hiv fusion inhibitors - adverse effects (39) 39
antiretroviral therapy, highly active (38) 38
membrane-fusion (38) 38
peptide fragments - chemistry (38) 38
virus diseases (38) 38
hiv infections - immunology (37) 37
rna, viral - blood (37) 37
hiv fusion inhibitors - pharmacokinetics (36) 36
hiv-1 - isolation & purification (36) 36
peptide fragments - pharmacokinetics (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (636) 636
Spanish (18) 18
French (8) 8
Portuguese (5) 5
Chinese (4) 4
German (4) 4
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
PLoS Pathogens, ISSN 1553-7366, 02/2019, Volume 15, Issue 2, pp. e1007552 - e1007552
Combination antiretroviral therapy (cART) dramatically improves survival of HIV-infected patients, but lifelong treatment can ultimately result in cumulative... 
WILD-TYPE | ENTRY | ENVELOPE GLYCOPROTEIN | MICROBIOLOGY | T HOOK STRUCTURE | PEPTIDE | ENFUVIRTIDE | VIROLOGY | HEPTAD REPEAT | STRUCTURAL BASIS | GP41 CORE STRUCTURE | IMMUNODEFICIENCY-VIRUS TYPE-1 | PARASITOLOGY | Antibodies, Neutralizing | Enfuvirtide - pharmacology | HIV-1 - pathogenicity | Simian Immunodeficiency Virus - pathogenicity | Lipopeptides - therapeutic use | Enfuvirtide - therapeutic use | Humans | Drug Resistance, Viral | Macaca mulatta - immunology | Rats | Male | Anti-Retroviral Agents | HIV Fusion Inhibitors - pharmacology | Rats, Sprague-Dawley | Viral Load | Virus Internalization | HIV Fusion Inhibitors - therapeutic use | Macaca mulatta - metabolism | Animals | HEK293 Cells | HIV Infections - therapy | Simian Acquired Immunodeficiency Syndrome - therapy | Treatment outcome | Antiviral agents | Analysis | Dosage and administration | Research | Drug therapy | HIV infection | Peptides | Toxicity | Zoology | Antibodies | Infections | Biology | Selectivity | Monkeys | Drug resistance | Drug development | Enfuvirtide | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Antiviral activity | Stearic acid | Pathogens | Animal sciences | Pharmacology | Injection | Fatty acids | Antiretroviral therapy | Mutants | Medicine | Infectious diseases | Inhibitors | Laboratory animals | Pharmacokinetics | Lipopeptides | Index Medicus | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
Journal of Molecular Biology, ISSN 0022-2836, 08/2019, Volume 431, Issue 17, pp. 3091 - 3106
Development of effective inhibitors of the fusion between HIV-1 and the host cell membrane mediated by gp41 continues to be a grand challenge due to an... 
x-ray crystallography | binding | calorimetry | fusion inhibitor | envelope glycoprotein | Proteins | Thermodynamics | Enfuvirtide | HIV (Viruses) | Analysis | Protein binding | Index Medicus
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 08/2017, Volume 7
Long-acting injectable antiretroviral (LA-ARV) drugs with low toxicity profiles and propensity for drugdrug interactions are a goal for future ARV regimens.... 
SIFUVIRTIDE | MULTIDISCIPLINARY SCIENCES | ANTIVIRAL POTENCY | RESISTANCE | INCREASES | FLUIDITY | INFECTION | CHOLESTEROL-CONJUGATED PEPTIDE | LIPID-COMPOSITION | HUMAN-IMMUNODEFICIENCY-VIRUS | ENFUVIRTIDE
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 10/2016, Volume 121, pp. 232 - 237
The site-specific conjugation of PEG to a peptide drug enfuvirtide is accomplished.The conjugate shows similar anti-HIV activity and action mechanism to... 
Enfuvirtide | Poly(ethylene glycol) | Conjugation | Human immunodeficiency virus | Pharmacokinetics | Fusion inhibitor
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2018, Volume 13, Issue 10, pp. e0206365 - e0206365
Human Immunodeficiency Virus-1 (HIV-1) entry is dependent on the envelope glycoprotein (Env) that is present on the virion and facilitates fusion between the... 
2G12 | V3 LOOP | CORECEPTOR | SOLUBLE CD4 | MULTIDISCIPLINARY SCIENCES | IMMUNODEFICIENCY-VIRUS TYPE-1 | ENVELOPE GLYCOPROTEIN | GP120 | HUMAN MONOCLONAL-ANTIBODIES | CELL-LINES | NEUTRALIZATION | Drug Evaluation, Preclinical - methods | Enfuvirtide - pharmacology | HIV-1 - pathogenicity | Cricetulus | HIV-1 - drug effects | Models, Molecular | Antibodies, Neutralizing - pharmacology | HIV Envelope Protein gp41 - chemistry | Virus Internalization - drug effects | Animals | Viral Fusion Proteins - chemistry | HIV Envelope Protein gp120 - chemistry | CHO Cells | Infection | Viral antibodies | Antiviral agents | Analysis | HIV testing | Antibodies | HIV (Viruses) | Health aspects | Drug approval | Usage | Care and treatment | Enfuvirtide | Glycoproteins | Research | Licensing, certification and accreditation | HIV infection | Pediatrics | Regulatory agencies | Viruses | Infections | Assaying | Proteins | Immunology | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Penicillin | Membrane fusion | CCR5 protein | Immunoglobulins | Departments | Glycoprotein gp41 | Glycoprotein | Cell membranes | FDA approval | Cell membranes (biology) | CXCR4 protein | CD4 antigen | Membrane proteins | Virology | Domains | Medicine | Infectious diseases | Inhibitors | Glycoprotein gp120 | Binding sites | Neutralization | Index Medicus | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
Journal of Virology, ISSN 0022-538X, 2017, Volume 91, Issue 1
Journal Article
Journal of Virology, ISSN 0022-538X, 2019, Volume 93, Issue 11
HIV infection requires lifelong treatment with multiple antiretroviral drugs in a combination, which ultimately causes cumulative toxicities and drug... 
HIV-1 | T-20 | HIV-2 | Lipopeptide | Fusion inhibitor | WILD-TYPE | GLYCOPROTEIN GP41 | ENVELOPE PROTEIN | CONJUGATED PEPTIDE | ENFUVIRTIDE | MEMBRANE-FUSION | fusion inhibitor | VIROLOGY | lipopeptide | LIPID-COMPOSITION | CAVEOLIN-1 BINDING DOMAIN | VIRAL ENTRY | HIV ENTRY
Journal Article
JOURNAL OF VIROLOGY, ISSN 0022-538X, 06/2019, Volume 93, Issue 11
Binding of the gp120 surface subunit of the envelope glycoprotein (Env) of HIV-1 to CD4 and chemokine receptors on target cells triggers refolding of the gp41... 
HIV-1 | DESIGN | ENTRY | TYPE-1 GP41 | POTENT INHIBITORS | resistance | ENFUVIRTIDE | fusion | fusion inhibitor | VIROLOGY | HELICAL DOMAIN | gp41 | INNER DOMAIN | INTERMEDIATE | conformational changes | COILED-COIL
Journal Article
Journal Article
Organic and Biomolecular Chemistry, ISSN 1477-0520, 2016, Volume 14, Issue 33, pp. 7875 - 7882
Lengthy peptides corresponding to the C-terminal heptad repeat (C-peptides) of human immunodeficiency virus type 1 (HIV-1) gp41 are potent inhibitors against... 
1ST | GP41 | ENFUVIRTIDE-RESISTANT HIV-1 | BIOLOGICAL EVALUATION | CHEMISTRY, ORGANIC | MECHANISMS | POCKET | MULTIFUNCTIONAL DOMAINS | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2008, Volume 359, Issue 4, pp. 355 - 365
Journal Article